lifestyle.pluralist.com

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Written by

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors – NEWSnet – News… as it used to be

More Press Releases

April 25, 2026

Rosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation – ADMA

April 25, 2026

Workforce Fatigue Emerging as Overlooked Safety Risk in Gulf Coast Industrial Operations

April 25, 2026

Harrisburg Web Design Company Encourages Small Businesses to Treat Their Website Like a Digital Employee

April 25, 2026

Expert Matchmaker in Portland Report by CX Research Institute